ESSA Pharma Inc. (EPIX) Given Average Rating of “Buy” by Analysts

Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have earned a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company.

Brokers have set a one year consensus price objective of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 175 out of 265 based on the ratings given to its competitors.

A number of brokerages recently commented on EPIX. Zacks Investment Research upgraded ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Tuesday, January 16th. Bloom Burton upgraded ESSA Pharma from a “hold” rating to a “buy” rating in a research report on Thursday.

Shares of ESSA Pharma (EPIX) opened at $0.23 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of -1.32. ESSA Pharma has a twelve month low of $0.15 and a twelve month high of $3.59.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings data on Monday, December 11th. The company reported ($0.09) earnings per share for the quarter. equities research analysts predict that ESSA Pharma will post -0.49 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “ESSA Pharma Inc. (EPIX) Given Average Rating of “Buy” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.

Leave a Reply